Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Biologic; Inadequate”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01353859
What this trial is testing

RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 39
Post-approval studies (Phase 4)Study completedNCT00967538
What this trial is testing

Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments

Who this might be right for
Psoriasis
Innovaderm Research Inc. 89
Not applicableStudy completedNCT04149587
What this trial is testing

Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 252
Large-scale testing (Phase 3)Ended earlyNCT01410695
What this trial is testing

Masitinib in Refractory Active Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis (RA)
AB Science 324
Large-scale testing (Phase 3)Study completedNCT00891020
What this trial is testing

Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 886
Large-scale testing (Phase 3)Study completedNCT01063062
What this trial is testing

A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 107
Large-scale testing (Phase 3)Study completedNCT02706847
What this trial is testing

Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

Who this might be right for
Rheumatoid Arthritis
AbbVie 499
Not applicableUnknownNCT04438642
What this trial is testing

Biological and Esthetic Evaluation of Ceramic Onlay With Different Preparation Designs

Who this might be right for
Unsatisfactory Restoration of ToothCarious Teeth
Ahmed Adel Mahmoud Gadallah 38
Large-scale testing (Phase 3)Study completedNCT04134728
What this trial is testing

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Who this might be right for
Arthritis, Rheumatoid
GlaxoSmithKline 550
Large-scale testing (Phase 3)Study completedNCT01844518
What this trial is testing

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Who this might be right for
Active Polyarticular Juvenile Idiopathic Arthritis
Bristol-Myers Squibb 219
Large-scale testing (Phase 3)Ended earlyNCT03970837
What this trial is testing

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Who this might be right for
Arthritis, Rheumatoid
GlaxoSmithKline 1,764
Post-approval studies (Phase 4)Study completedNCT01149057
What this trial is testing

RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 145
Large-scale testing (Phase 3)Study completedNCT03104400
What this trial is testing

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Who this might be right for
Psoriatic Arthritis
AbbVie 1,705
Not applicableLooking for participantsNCT06899204
What this trial is testing

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Who this might be right for
Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
Pfizer 150
Testing effectiveness (Phase 2)Ended earlyNCT01636843
What this trial is testing

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Who this might be right for
InflammationRheumatoid Arthritis
Novo Nordisk A/S 298
Post-approval studies (Phase 4)Study completedNCT01034397
What this trial is testing

Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 54
Not applicableStudy completedNCT01362062
What this trial is testing

Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 110
Large-scale testing (Phase 3)Active Not RecruitingNCT06241118
What this trial is testing

Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Who this might be right for
Dermatitis Atopic
Sanofi 464
Testing effectiveness (Phase 2)Study completedNCT03682705
What this trial is testing

Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis (RA)
AbbVie 242
Large-scale testing (Phase 3)Study completedNCT03104374
What this trial is testing

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

Who this might be right for
Psoriatic Arthritis
AbbVie 642
Next Page